Understand the metabolic partnering landscape using intelligence from 649 real-world collaboration and licensing deals.
Metabolic Collaboration and Licensing Deals 2019-2026 provides comprehensive intelligence on 649 partnering deals involving metabolic assets, technologies and development programs.
Metabolic disease represents a major area of pharmaceutical and biotechnology innovation, encompassing large chronic disease populations, evolving treatment approaches and significant commercial opportunity across multiple indications and technologies.
The report brings this partnering activity together in one resource, enabling users to understand who is partnering, which metabolic opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in metabolic partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad metabolic benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable metabolic transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking metabolic opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable metabolic assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building metabolic portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying metabolic deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Metabolic Collaboration and Licensing Deals 2019-2026 provides comprehensive intelligence on 649 partnering deals involving metabolic assets, technologies and development programs.
Metabolic disease represents a major area of pharmaceutical and biotechnology innovation, encompassing large chronic disease populations, evolving treatment approaches and significant commercial opportunity across multiple indications and technologies.
The report brings this partnering activity together in one resource, enabling users to understand who is partnering, which metabolic opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in metabolic partnering.
Understand the metabolic partnering landscape
The report analyzes metabolic dealmaking from 2019 to 2026, including:
- Trends in metabolic partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active metabolic dealmakers
- Leading deals by disclosed value
- How metabolic partnering activity is evolving
Benchmark metabolic deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading metabolic dealmakers and prospective partners
The report identifies the most active companies in metabolic partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking metabolic opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant metabolic indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies, targets or therapeutic approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across metabolic indications and targets
Metabolic disease encompasses multiple indications and therapeutic targets with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad metabolic benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how metabolic agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected metabolic transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive metabolic deal directory
The report includes a comprehensive directory of 649 metabolic collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable metabolic transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking metabolic opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable metabolic assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building metabolic portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide metabolic intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying metabolic deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in metabolic dealmaking
Chapter 3 - Financial deal terms for metabolic partnering
Chapter 4 - Leading metabolic deals and dealmakers
Chapter 5 - Metabolic contract document directory
Chapter 6 - Metabolic dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3DR Labs
- 4P-Pharma
- 23andMe
- 180 Life Sciences
- Abbisko Therapeutics
- Abbott Laboratories
- AbCellera Biologics
- Abeona Therapeutics
- AcelaBio
- Acentrus Specialty
- Acenzia
- Aceragen
- Ache
- Acuitas Therapeutics
- Adaptive Phage Therapeutics
- Adhera Therapeutics
- Advanz Pharma
- AdventHealth
- Aeglea BioTherapeutics
- AEterna Zentaris
- Aevi Genomic Medicine
- AgBiome
- AgeX Therapeutics
- AiCuris
- Akcea Therapeutics
- Akero Therapeutics
- Albert Einstein College of Medicine
- Albireo
- Alfasigma
- Aliada Therapeutics
- Aligos Therapeutics
- Alimentiv
- AliveCor
- Alkem Laboratories
- Allele Biotechnology and Pharmaceuticals
- AllerGenis
- Allevi 3D
- Almelo
- Alnylam Pharmaceuticals
- ALR Technologies
- ALTuCELL
- Alveus Therapeutics
- Amarna Therapeutics
- Amazentis
- Ambiopharm
- AM Chemicals
- A Menarini Diagnostics
- American Association for the Study of Liver Diseases
- American Diabetes Association
- Amgen
- Amicus Therapeutics
- AmideBio
- AMMTeK
- Amneal Pharmaceuticals
- Amolyt Pharma
- AMRA Medical
- Amyris
- Anagram Therapeutics
- Angers University
- Anivive Lifesciences
- Anji Pharma
- Antares Pharma
- Apellis Pharmaceuticals
- Apollon Formularies
- Apollo Therapeutics
- Applied DNA Sciences
- Applied Therapeutics
- APR Applied Pharma Research
- Arbor Biotechnologies
- Arch Biopartners
- Archer Daniels Midland Company
- Arecor
- Argon Medical Devices
- Arjuna Naturals
- Arrowhead Pharmaceuticals
- Arzeda
- Ascendis Pharma
- Ascensia Diabetes Care
- Ascletis
- Asklepios Biopharmaceutical
- Aspect Biosystems
- Astellas Pharma
- Astex Pharmaceuticals
- AstraZeneca
- ATUM
- Avicanna
- Avrobio
- Axcella
- AXIM Biotechnologies
- Axovant Gene Therapies
- Baliopharm
- BaoDao Feed
- Basepaws
- Bavarian Brewing & Beverage Institute
- Baxter International
- Bayer
- BCD Bioscience
- Beam Therapeutics
- Beijing University of Chinese Medicine
- Bened Biomedical
- Benuvia Therapeutics
- Beren Therapeutics
- Berg
- Beta Bionics
- Better Therapeutics
- Beyond Type 1
- Bigfoot Biomedical
- Bill and Melinda Gates Foundation
- Bioadaptives
- biOasis Technologies
- Biocon
- BIOCORP
- Biodexa Pharmaceuticals
- BioHarvest Sciences
- BIOHM Health Inc
- BioLinQ
- Biolojic Design
- BioMarin Pharmaceutical
- BioMed X Innovation Center
- BioPep
- Biosidus
- Biosplice
- Bird Foundation
- Boehringer Ingelheim
- Bond Pet Foods
- Bonne Santé Group
- BPGbio
- Brand Institute
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- BrightInsight
- Brightseed
- Broad Institute
- Bruker
- Bruno Farmaceutici
- Bunker Pflanzenextrakte
- c-LEcta
- CamDiab
- CAMP4 Therapeutics
- Camurus
- Can-Fite BioPharma
- CANbridge Pharmaceuticals
- Cantex Pharmaceuticals
- Capillary Biomedical
- Cardiff University
- Cardinal Health
- Cardiovascular Solutions of Central Mississippi
- Carisma Therapeutics
- CASI Pharmaceuticals
- Catalent
- Cellarity
- CELLINK
- Celloram
- Centene
- Center for Genomic Regulation
- Centogene
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Centrus Health Clinics
- Century Therapeutics
- Chemify
- Chiasma
- Chiesi Farmaceutici
- Chiesi Global Rare Diseases
- Children's Hospital at Montefiore
- Children's Hospital Boston
- Chongqing Yao Pharmaceutical
- ChromaDex
- Cibus Global
- Citrine Medicine
- City of Hope
- Civica Rx
- CJ CheilJedang
- Clarus Therapeutics
- Clinigen
- CN Bio
- Code Biotherapeutics
- Codexis
- Columbia University
- Companion Medical
- Conatus Pharmaceuticals
- Consilient Health
- Cooper Aerobics
- Corvium
- Cosmos
- COUR Pharmaceutical
- Covance
- Creative Medical Technologies
- Crinetics
- CRISPR Therapeutics
- Critical Path Institute (C-Path)
- Crossject
- CSPC Pharmaceutical Group
- Cukierman & Co Life Sciences
- Cure Genetics
- Cycle Pharmaceuticals
- Cyclo Therapeutics
- CymaBay Therapeutics
- Cystic Fibrosis Foundation
- Cytoo
- Dawn Health
- Deargen
- Decode Health
- Deep Apple Therapeutics
- Deerfield Management
- Defense Health Agency (US)
- DEKA Research and Development
- Delta 4
- Delve Health
- Department of Veterans Affairs
- Dewpoint Therapeutics
- DexCom
- Diabeloop
- Diabetes Research Connection
- Diabetes Research Institute
- Diabetes Singapore
- Diamyd Medical
- Dicerna Pharmaceuticals
- DigiLab
- Diomics
- Diurnal
- DKSH
- DNAnexus
- DolCas Biotech
- Dong-A ST
- DoveTree Medicines
- DreaMed Diabetes
- Duke Clinical Research Institute (DCRI)
- Duke University
- DuPont Pharmaceuticals
- Dyadic International
- Dyno Therapeutics
- EatLove
- Eccogene
- Echosens
- EffRx Pharmaceuticals
- Ei.Ventures
- EirGen Pharma
- Elanco
- Elcelyx Therapeutics
- Eledon Pharmaceuticals
- Eleven Biotherapeutics
- Eli Lilly
- ELNA Medical
- Elo Life Systems
- Elvinix
- Emmyon
- Enable Biosciences
- ENDRA Life Sciences
- Engitix
- Engrail Therapeutics
- Enogenesis
- Entera Bio
- Enzolytics
- Enzyvant Science
- Epitomee Medical
- Er-Kim
- Eracal Therapeutics
- Eton Pharmaceuticals
- European Union Regional Development Fund
- European Wellness Biomedical Group
- EVA Pharma
- EverlyWell
- Eversana
- EVerZom
- Evgen Pharma
- Evidation Health
- Evo Foods
- EVOQ Therapeutics
- Evotec
- Evozyne
- Ewopharma
- ExCEEd Orphan
- First Wave Bio
- FitBit
- Flagship Biosciences
- Fondazione San Raffaele
- Fondazione Telethon
- Fonterra
- Food and Drug Administration (FDA)
- Fosun Pharmaceutical
- Foundation for Diabetes Research
- FUJIFILM Cellular Dynamics
- Fundacion Progreso y Salud
- G3 Therapeutics
- G42 Healthcare
- Gain Therapeutics
- Galapagos
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Gan & Lee
- Gannex Pharma
- Gastrologix
- GATC Health
- GC Pharma
- GE Healthcare
- GEMMA Biotherapeutics
- GeneDX
- Genentech
- General Automation Lab Technologies
- Generation Bio
- Generex Biotechnology
- Genethon
- Genevant Sciences
- Genfit
- Genome Quebec
- Genomma Lab Internacional
- Genprex
- Gensaic
- Gensci
- George Clinical
- Gilead Sciences
- Ginkgo BioWorks
- Glenmark Pharmaceuticals
- Global Liver Institute
- Glooko
- GlucoModicum
- Glympse Bio
- Glytec
- Goldfinch Bio
- Graviton Bioscience
- Group K Diagnostics
- GSK
- Halberd
- Hamilton Company
- Hanmi Pharmaceutical
- Hansa Biopharma
- Harvard Medical School
- Haselmeier
- Hatch Medical
- HAYA Therapeutics
- Health2Sync
- Healthimation
- Health Network Laboratories
- Healthy.io
- Healthy Grain
- Helix
- HemoShear
- Hepalys Pharma
- HepaTx
- Hepion Pharmaceuticals
- HepQuant
- Hill's Pet Nutrition
- HistoIndex
- HitGen
- HK inno.N
- Horizon Discovery
- Horizon Therapeutics
- Humacyte
- Hygieia
- I-mab
- i-SENS
- iECURE
- Illumina
- Imagine Pharmaceuticals
- Imaware
- Immedica
- Immusoft
- Immuthera
- Imperial College London
- Indiana University
- Ingredion
- Innovate UK
- Innovation Zed
- Innovent Biologics
- Insilico Medicine
- Insitro
- InSphero
- Institute of Endocrinology
- Metabolism
- and Reproduction
- Insulet
- Intact Therapeutics
- Integral Molecular
- InterAx Biotech
- Intercept Pharmaceuticals
- International Diabetes Federation (IDF)
- International Niemann-Pick Disease Registry
- Inventiva
- Invitae
- Ionis Pharmaceuticals
- Ipsen
- IQVIA
- Ironwood Pharmaceuticals
- iSage Rx
- Itochu
- iTolerance
- Jackson Laboratory
- Jadeite Medicines
- Janssen Pharmaceuticals
- Janssen Research & Development
- Janssen Therapeutics
- Jasper Therapeutics
- JCR Pharmaceuticals
- Jennewein Biotechnologie
- Jiangsu Chia Tai Tianqing Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jinggangshan University
- Johns Hopkins Medicine (JHM)
- Johns Hopkins University
- Journey Medical
- Jugular
- Jumpcan Pharmaceutical
- Juntendo University
- Juvena Therapeutics
- Juvenescence
- Juvenile Diabetes Research Foundation
- JW Pharmaceutical
- Kadimastem
- Kahn-Sagol-Maccabi
- Kaken Pharmaceutical
- Kaleido Biosciences
- Kalsec
- Katana Pharmaceuticals
- Key2Brain
- KeyBioScience
- Klue
- Know Labs
- Kore
- Korro Bio
- Kyowa Hakko Kirin
- Labcyte
- Laboratory Corporation of America
- Lannett
- Lark Technologies
- Launch Therapeutics
- Leona M and Harry B Helmsley Charitable Trust
- Lexicon Pharmaceuticals
- LG Life Sciences
- LifeOmic
- LifeScan
- Lipigon Pharmaceuticals
- Lipocine
- Livongo Health
- LogicBio Therapeutics
- Lonza
- LUCA Science
- Lumen Biomedical
- Luminex
- Lumos Pharma
- Lurie Children's Hospital of Chicago
- LyGenesis
- LY Research
- Lysando
- Lysogene
- mAbXience
- Madrigal Pharmaceuticals
- Mammoth Biosciences
- Mandos
- MannKind Biopharmaceuticals
- Martin Pharmaceuticals
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Mass General Brigham
- Max Biopharma
- Mayo Clinic
- Maze Therapeutics
- McGill University
- McQuade Center for Strategic Research and Development
- MEDIAN Technologies
- Medical College of Wisconsin
- Medical University of South Carolina
- MediciNova
- Medicox
- MedImmune
- Medipal Holdings
- Medisca
- Medison Pharma
- Medtronic
- Meitheal Pharmaceuticals
- Melior Pharmaceuticals
- Merck and Co
- Merck KGaA
- Merieux NutriSciences
- Merz
- Mesh Bio
- Metaba
- Meta Healthcare
- MetaSight Diagnostics
- Metro Health
- Metsera
- Microba Life Sciences
- MiNA Therapeutics
- Minerva Foods
- Minovia Therapeutics
- Miromatrix Medical
- Mirum Pharmaceuticals
- Mission Bio
- Mitobridge
- Mitsubishi Tanabe Pharma
- MJH Life Sciences
- Moderna
- ModeX Therapeutics
- Modular Medical
- Mount Sinai Health System
- mPulse Mobile
- MRM Health
- MThera Pharma
- MultiOmic Health
- Murdoch University
- MyBiotics Pharma
- MySugarWatch DuoPack
- Namocell
- NAMUH
- Nano-X Imaging
- NanoVation Therapeutics
- NASH Network
- National Cerebral and Cardiovascular Disease Research Center
- National Heart
- Lung and Blood Institute
- National Institute of Arthritis and Musculoskeletal Diseases
- National Institute of Child Health and Human Development
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
- National Organization for Rare Disorders
- National Research Council Canada
- National University of Singapore
- Navidea Biopharmaceuticals
- Nebraska Medicine
- Nemaura Medical
- Nemysis
- Neogen
- Neomorph
- NephroDI Therapeutics
- Nestle Health Science
- Neuraxpharm
- NeuroBiogen
- NeuroBo Pharmaceuticals
- Neurocrine Biosciences
- Neurodon
- NeuroFront
- Newsoara Biopharma
- New Wave Ventures
- Neximmune
- NGM Biopharmaceuticals
- Nicoya
- Nimbus Therapeutics
- NIMIUM Therapeutics
- NLC Pharma
- Norgine
- Northwestern University
- NorthX Biologics
- Novaremed
- Novartis
- Novasep
- Novitium Pharma
- Novo Integrated Sciences
- Novo Nordisk
- Nuformix
- Numares
- NutraFuels
- Nutrition21
- Ocean Spray Cranberries
- Ochre Bio
- Ohio State University
- Okava Pharmaceuticals
- OliX Pharmaceuticals
- Omega Therapeutics
- OmniaBio
- One World Products
- Ono Pharmaceutical
- Onward Therapeutics
- OPKO Biologics
- OPKO Health
- Optithera
- Optomed
- Oramed Pharmaceuticals
- Orchard Therapeutics
- Oregon Health Sciences University
- Orgenesis
- Origin Agritech
- OrphanPacific
- OrsoBio
- OSE Immunotherapeutics
- OSI Pharmaceuticals
- Oslo University Hospital
- OTR Therapeutics
- Otsuka
- Ovation
- Oxford Biomedica Solutions
- Pancryos
- Pandion Therapeutics
- Paraza Pharma
- Particles for Humanity
- Parvus Therapeutics
- Passage Bio
- PathAI
- Pathalys Pharma
- Patia
- PegBio
- Penn State Microbiome Center
- PeptiDream
- Performance Inspired Nutrition
- PerkinElmer
- Perspectum Diagnostics
- Pfizer
- PharmaCyte Biotech
- Pharmanest
- Pharmanovia
- Pharmathen
- Pharmavite
- Phenex
- Phillips-Medisize
- PhoreMost
- Photys Therapeutics
- Phytolon
- Piramal
- Pliant Therapeutics
- Pluristem Therapeutics
- Pluristyx
- Polyganics
- Population Health Partners
- PRA Health Sciences
- Precision Diabetes
- Premier Inc
- Pressure BioSciences
- ProBioGen
- Processa Pharmaceuticals
- Procyon Technologies
- Profil Institute for Clinical Research
- ProLynx
- Promethera Biosciences
- ProPath
- Provention Bio
- Psyence Therapeutics
- Pulmatrix
- Purnovate
- Qilu Pharmaceutical
- Quell Therapeutics
- Quest Diagnostics
- Radius Health
- Rallybio
- Rani Therapeutics
- Rare Disease Company Coalition
- Raziel Therapeutics
- RC2
- Readout Health
- Reata Pharmaceuticals
- Recordati
- Redox
- Redwire
- Regeneron Pharmaceuticals
- Regenxbio
- Regional Cancer Institute of Montpellier
- Regor Therapeutics
- Relation Therapeutics
- Relief Therapeutics
- Remedium Bio
- RenalytixAI
- Renown Institute for Health Innovation
- Replicate Bioscience
- Resolution Therapeutics
- Revive Therapeutics
- Rezolute
- Rho
- Rimidi
- Ripe Technology
- Roche
- Roche Diagnostics
- RTW Investments
- SafeTraces
- Sagimet Biosciences
- Salipro Biotech
- Salix Pharmaceuticals
- Sanacor
- Sandhill One
- SanegeneBio
- Sanofi
- Sanofi US Services
- Sanwa Kagaku Kenkyusho
- Science 37
- Scientific Research Council
- Scilex Holding
- Sciwind Biosciences
- SCM Pharma
- Seal Rock Therapeutics
- Second Genome
- Selecta Biosciences
- Senda Biosciences
- Senseonics
- Senti Biosciences
- Sentynl Therapeutics
- Seoul National University
- Septerna
- Seraxis
- Sernova
- SFC Fluidics
- Shanghai Jiao Tong University
- Shenzhen Chipscreen Biosciences
- Shionogi
- Shionogi Pharma
- Sichuan Deebio Pharmaceutical
- Siemens Healthineers
- Sigilon Therapeutics
- Silence Therapeutics
- Singapore General Hospital
- Sino Biopharmaceutical
- Sinopia Biosciences
- Sirion Biotech
- Sirona Biochem
- SocialDiabetes
- Societal CDMO
- Solarea Bio
- SomaLogic
- Sonnet BioTherapeutics
- SOOIL Development Company
- Sookmyung Women's University
- Sosei
- Spark Therapeutics
- Sparrow Pharmaceuticals
- SPC Korea
- Steno Diabetes Center
- SteroTherapeutics
- Stevanato
- Structure Therapeutics
- Sumitomo Dainippon Pharma
- Summit Clinical Research
- Sun Genomics
- Sunshine Lake Pharma
- Surrozen
- Suzhou Ribo Life Science
- Suzhou Ribo Life Sciences
- Suzhou Siran Biotechnology
- Synbiotech
- Synbiotic Health
- SynerK
- Syneron Bio
- Synlogic
- Synspira
- Syntax Bio
- Synthetic Biologics
- T-Cell Protect Hellas
- Taisho Pharmaceutical
- TaiwanJ Pharmaceuticals
- Takara Bio
- Takeda Pharmaceutical
- Tandem Diabetes Care
- Target RWE
- Tate & Lyle
- Taysha Gene Therapies
- Technomark Life Sciences
- Teijin
- Terns Pharmaceuticals
- Terumo
- TeselaGen
- Tespo
- Tetra Bio-Pharma
- Tetris Pharma
- Texas A&M University
- Theracell
- TheracosBio
- The United Laboratories
- Thorne HealthTech
- Tianjin JuveStar Biotech
- Tiburio Therapeutics
- Tidepool
- Tnuva Group
- Todos Medical
- Tome Biosciences
- Tonghua Dongbao Pharma
- TONIX Pharmaceuticals
- Torrent Pharmaceuticals
- Tottori University
- TPMENA
- TransThera
- TransThera Sciences
- TreeFrog Therapeutics
- True Diagnostics
- TRx Biosciences
- Twinlab
- Twist Bioscience
- UK Biobank
- Ultragenyx Pharmaceuticals
- Undisclosed Company
- Unilever
- United Immunity
- Universe Pharmaceuticals
- University Hospitals Accountable Care Organization
- University Libre of Brussels
- University of Alberta
- University of British Columbia
- University of California
- San Diego
- University of California
- San Diego (UCSD) School of Medicine
- University of California Irvine
- University of California Los Angeles
- University of California San Francisco
- University of Chicago
- University of Colorado
- University of Edinburgh
- University of Florida
- University of Geneva
- University of Maryland School of Medicine
- University of Massachusetts
- University of Miami
- University of Michigan
- University of Nebraska
- University of New Mexico
- University of North Carolina
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Sheffield
- University of Technology Sydney
- University of Texas
- University of Toronto
- University of Virginia
- University of Washington
- University of West Indies
- University of Wisconsin-Madison
- UP International
- Upsher-Smith
- USANA Health Science
- UW Medicine
- Valbiotis
- Valley Oils Partners
- Valo Health
- Vanderbilt University
- Variant Bio
- VELL Health
- Ventus Therapeutics
- Verantos
- Veravas
- Verdiva Bio
- Versiti Blood Research Institute
- Vertex Pharmaceuticals
- Verve Therapeutics
- VGI Health Technology
- ViaCyte
- Vifor Pharma
- Viome
- Vipergen
- VIPUN Medical
- Viralgen
- Vir Biotechnology
- Virginia Commonwealth University
- Virginia Tech
- Virtual Health Partners
- VisionQuest Biomedical
- Visirna Therapeutics
- VistaGen Therapeutics
- Vitro Biopharma
- Vivani Medical
- Vivet Therapeutics
- Vivici
- Vivtex
- VOTIS Subdermal Imaging Technologies
- vTv Therapeutics
- Wake Forest University
- Wake Forest University School of Medicine
- Wanbang Biopharmaceuticals
- Washington University in St Louis
- WaVe Lifesciences
- Weizmann Institute
- Wellcome Trust
- WellDoc
- WellGen
- Willow Biosciences
- Winhealth Pharma Group
- W L Gore
- Worldwide Clinical Trials
- Wuhan General Group
- XERIS Pharmaceuticals
- Xlife Sciences
- Xoma
- XtalPi
- Yale University
- Yarrow Bioscience
- Yeda Research and Development Company
- Yili Industrial Group
- Ymir Genomics
- Ypsomed
- Yuhan Corporation
- Zag Bio
- Zealand Pharma
- Zelira Therapeutics
- Zhejiang Hisun Pharmaceutical
- Zifo
- ZyVersa Therapeutics
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
